Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

REGN 12.17.2024

Full Press ReleaseSEC FilingsOur REGN Tweets

About Gravity Analytica

Recent News

  • 02.04.2025 - Regeneron Pharmaceuticals Q4 2024 Earnings Conference Call
  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
Regeneron Pharmaceuticals, Inc.
  • Facebook
  • LinkedIn
  • Twitter
  • RSS Feeds
December 17, 2024 at 4:05 PM EST
Back

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y.,Dec. 17, 2024(GLOBE NEWSWIRE) --Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN) will webcast its presentation at the 43rdAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 13, 2025. The presentation is scheduled for2:15 p.m. Pacific Time(5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page ofRegeneron's website athttp://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

AboutRegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneronpushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such asVelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center®and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visitwww.Regeneron.comor followRegenerononLinkedIn,Instagram,FacebookorX.

Contact Information:Investor RelationsRyan Crowe914.847.8790ryan.crowe@regeneron.com

Corporate CommunicationsChristina Chan914.847.8827christina.chan@regeneron.com

Primary Logo

Source: Regeneron Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com